Estimating Vaccine Efficacy From Secondary Attack Rates
利用二代罹患率估计疫苗效力AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确的是传播单元相关性下的疫苗效力估计,未说明因果识别设计或网络干扰模型。
利用二代罹患率估计疫苗效力AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Epidemiologists have used secondary attack rates (SARs) to estimate the protective effects of vaccination since the 1930s. SARs can also be used to estimate the effect of vaccination on reducing infectiousness in breakthrough cases. The conventional SAR approach has been to pool the denominators and numerators across transmission units, then to use a confidence interval for a simple relative risk. We demonstrate appropriate model-based methods to estimate vaccine efficacy (VE) from SARs using generalized estimating equations taking correlation within transmission units into account. The model-based procedures require transformation of the parameter estimates to the SAR scale to obtain vaccine efficacy estimates. Appropriate confidence intervals are then based on the bootstrap, with resampling done by transmission unit. We show that the usual confidence intervals are too narrow. We estimated the effect of pertussis vaccination on person-to-person transmission. The results show that pertussis vaccination reduces the ability of a breakthrough clinical case to produce other clinical cases. The methods can be used in evaluating VE for susceptibility and infectiousness from SARs in other infectious diseases.